Navigation Links
DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium
Date:3/25/2009

Thirteen Abstracts Will Be Featured at Annual Kidney Care Meeting

EL SEGUNDO, Calif., March 25 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that company representatives will present thirteen abstracts at the National Kidney Foundation's 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 in Nashville, TN. The meeting is a platform for the nation's leading renal health care providers to learn about new developments in the field of nephrology and CKD care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

Allen R. Nissenson MD, Chief Medical Officer at DaVita says, "DaVita is continuing to lead the renal community in generating important new knowledge to improve the outcomes for patients with kidney disease. This commitment to high quality clinical research is clearly evident in the thirteen abstracts being presented at the National Kidney Foundation meeting this year."

DaVita's top ten clinical initiatives for 2009 include: striving for reduction of first-year mortality rates and reducing catheter use. At this year's National Kidney Foundation Clinical Meeting, DaVita will focus on several key research initiatives in the areas of CKD, new incident dialysis patients, and integrated pharmacy management. Highlights from these scheduled presentations will include:

  • Improved Results in CKD Management: Recent data reveals superior outcomes in the areas of CKD and mortality, anemia, incident patient management and phosphorus and coronary artery calcification. DaVita researchers note a nearly 50 percent drop in one-year mortality in Detroit area, DaVita-managed CKD clinics compared to Renal Network 11 (12.8% vs. 22.6%);
  • Advances in Streamlining the Patient Onboarding Process: Data on DaVita's IMPACT(TM) (Incident Management of Patients, Actions Centered on Treatment) program - a pilot project implemented in 44 DaVita centers around the nation focusing on patient education and important clinical outcomes - demonstrates how this comprehensive approach reduces mortality of incident patients. Results showed a reduction in 90-day mortality nearly two percentage points lower (6.14% vs. 7.98%) among IMPACT versus nonIMPACT patients; and
  • Integrated Pharmacy Management Impacts Clinical Outcomes: DaVita Rx(sm) pharmacy program removes common access barriers for patients, such as transportation and access to the medications they require. Researchers observed significantly improved clinical outcomes in DaVita Rx patients compared to non-DaVita Rx patients.

In addition to DaVita's research initiatives on CKD, IMPACT and DaVita Rx, the following is a complete list of abstracts scheduled for presentation:

      -- Title:  First Year Dialysis Mortality in Patients Previously Enrolled
         in a Structured Chronic Kidney Disease (CKD) Program
         Authors:  Joel M. Topf(1), Robert Provenzano(2), Steve Wilson(3),
         Ajay Chokshi(3) and Amy Bogan(3)

         (1)St. John Hospital & Medical Center, Detroit, Michigan,(2)Office of
         the Chief Medical Officer, DaVita Inc., El Segundo, CA, (3)DaVita
         Inc., El Segundo, CA

      -- Title:  Analysis of Potassium Profiles Among Hemodialysis (HD)
         Patients
         Authors:  John Robertson, Debbie Benner, Ronald Levine
         DaVita Inc., El Segundo, CA

      -- Title:  Day-To Day, Week-To-Week, and Day-Of-Week Variation in Tests
         of Anemia and Iron Status in Hemodialysis Patients
         Authors:  David B. Van Wyck(1), Harry Alcorn(1), Resmi Gupta(2)

         (1)DaVita, Inc., El Segundo, CA, (2)Vital Systems, Inc.,
         Schaumburg,IL

      -- Title:  Benefit of Using Visual Teaching Tools for Phosphorus Control
         in Hemodialysis Unit
         Authors:  Carol Allen
         DaVita Inc., Selma, CA

      -- Title:  Binder Consumption as a Function of Time: A Linear Model for
         Lowering Elevated Phosphorus Levels by Improving Binder Timing
         Authors:  Mark A. Livingston
         DaVita Inc., Warren, MI

      -- Title:  Mortality of 5-Year Time-Averaged Low Serum Calcium <8.5
         mg/dL in Subgroups of Hemodialysis (HD) Patients
         Authors:  Jessica E Miller(1), Elani Streja(1), Csaba P Kovesdy(2),
         David Van Wyck(3), Allen R. Nissenson(3), and Kamyar Kalantar-
         Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; and (3)DaVita Inc, El Segundo, CA

      -- Title:  Association of Serum Alkaline Phosphatase and Coronary Artery
         Calcification in Hemodialysis Patients
         Authors:  Ronney Shantouf(1), Mehdi Rambod(1), Csaba P Kovesdy(2),
         Naser Ahmadi(1), Allen R. Nissenson(3), Matthew J Budoff(1), and
         Kamyar Kalantar-Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; and (3)DaVita Inc, El Segundo, CA

      -- Title:  Mortality-Predictability of Weight Gain vs Weight Loss Over 6
         Months in Maintenance Hemodialysis (MHD) Patients
         Authors:  Kamyar Kalantar-Zadeh(1), Elani Streja(1), Csaba P
         Kovesdy(2), Allen R. Nissenson(3), and Joel D Kopple(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; (3)DaVita Inc, El Segundo, CA

      -- Title:  Improved Outcomes Post Enrollment in High Touch, Tailored
         Pharmacy--Meeting the Patients' Need
         Authors:  Maricela Lara-Nevarez(1), Meredith Mathews(1), Chad
         Lennox(2)

         (1)DaVita Inc., El Segundo, CA (2)Dialysis Patient Citizens,
         Washington, DC

      -- Title:  Characteristics and Clinical Outcomes of US Pediatric
         Dialysis Patients at A Large Dialysis Provider
         Authors:  Allen R. Nissenson, Joe Weldon, and Joan Fieldhouse
         DaVita Inc., El Segundo, CA

      -- Title:  Incident Management of Hemodialysis Patients: Managing the
         First 90 Days
         Authors:  John Robertson, Pooja Goel, Grace Chen, Ronald Levine,
         Debbie Benner, and Amy Burdan
         DaVita Inc., El Segundo, CA

      -- Title:  Body Mass Index (BMI) and Survival in Polycystic Kidney
         Disease (PKD) Hemodialysis (HD) Patients
         Authors:  Elani Streja(1), Csaba P Kovesdy(2), Jenni Jing(1), Allen
         R. Nissenson(3), and Kamyar Kalantar-Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; (3)DaVita Inc., El Segundo, CA

      -- Title:  Comparing Death Risk of Polycystic Kidney Disease (PKD)
         Hemodialysis (HD) Patients to Non-PKD HD Patients
         Authors:  Elani Streja(1), Allen R. Nissenson(3), David VanWyck(3),
         Csaba P Kovesdy(2), and Kamyar Kalantar- Zadeh(1)

         (1)Harold Simmons Center & Cardiology, LABioMed at Harbor-UCLA,
         Torrance, CA; (2)Salem VA Medical Center, Salem, VA; (3)DaVita Inc.,
         El Segundo, CA

DaVita, IMPACT and DaVita Rx are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,400 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 110,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials and its community programs, please visit www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
2. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
3. DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
4. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
5. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
6. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
7. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
8. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  As a teenager, an active ... fever, which damaged his heart. He continued enjoying sports ... June 2013, Shepherd,s heart was giving out and he ... June 20, 2013, the Mesa, Arizona ... (TAH-t). Like a heart transplant, the SynCardia TAH-t is ...
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... is excited to announce the launch of its Mediceutical line of products, a line ... variety of clinical conditions. Founded in 2013, Forté spent more than two years researching ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Dr. Elyson ... wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, ... always problematic, they often are improperly erupted, resulting in risks of complications. By providing ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... of foundational nutrients that supports cellular and metabolic health. This synergistic combination of ... mg free-form curcumin, along with 150 mg of reduced glutathione and 200 mg ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of ... life forever with a same-day LASIK procedure at Christenbury Eye Center. The ... Jonathan Christenbury performed her surgery the same day as her in-office consultation and eye ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... industry, today announced that it was chosen as the Pharmaceutical News Provider of ... . The awards acknowledge the hard work and dedication of community members who ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
Breaking Medicine News(10 mins):